Compare GSK plc (GSK) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs SiTime Corporation — how do they compare? GSK plc trades at $52.8 (market cap $101.34B), while SiTime Corporation trades at $573.48 (market cap $18.34B). The key difference: GSK plc is far larger — about 5.5× SiTime Corporation's market cap, and GSK plc pays a 3.49% dividend while SiTime Corporation pays none. Which is the better fit depends on your goals.
| GSK | SITM | |
|---|---|---|
Market Cap | $101.34B | $18.34B |
Sector | Health | Technology |
52-Week High | $61.18 | $901.60 |
52-Week Low | $36.20 | $190.16 |
Enterprise Value | $121.95B | $17.56B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
SITM trades at $583.36, down 6.49% today, amid a bearish technical signal. The stock shows strong earnings beats in recent quarters but negative profitability margins. Recent news includes the completion of Renesas' timing business acquisition and strong AI-driven revenue growth. Cash flow trends indicate heavy investment activity in 2025, with a projected improvement in 2026.
Outlook is mixed; analyst consensus is strongly bullish with a $825 price target, but high valuation ratios and negative margins pose risks. The stock's near-term direction may hinge on Q2 2026 earnings due August 5, 2026, and execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
